The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD‐L1 expression and tumor‐infiltrating lymphocytes
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Medicine"
DOI: 10.1002/cam4.2580
Abstract: The aim of this study was to investigate the tumor microenvironment immune types (TMIT) based on tumor cell programmed cell death ligand 1 (PD‐L1) expression and tumor‐infiltrating lymphocytes (TILs) distribution and whether distinct TMIT subtypes… read more here.
Keywords: lung adenocarcinoma; infiltrating lymphocytes; expression tumor; tumor infiltrating ... See more keywords
Relationship and prognostic significance of IL‐33, PD‐1/PD‐L1, and tertiary lymphoid structures in cervical cancer
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Leukocyte Biology"
DOI: 10.1002/jlb.5ma0322-746r
Abstract: IL‐33, an epithelial‐derived cytokine, functions as an alarmin for the immune system in the tumor microenvironment (TME). However, the expression and role of IL‐33 on cervical cancer remain unclear. The aim of this study was… read more here.
Keywords: cervical cancer; relationship; tumor; expression tumor ... See more keywords
PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma
Sign Up to like & getrecommendations! Published in 2020 at "Virchows Archiv"
DOI: 10.1007/s00428-020-02751-6
Abstract: The response rate to checkpoint inhibitors for women with high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum (HGSC) is modest, and development of predictive biomarkers is needed. The main focus has been on… read more here.
Keywords: grade serous; carcinoma; high grade; expression tumor ... See more keywords
Vitamin D inhibits the Staphylococcal enterotoxin B-induced expression of tumor necrosis factor in microglial cells
Sign Up to like & getrecommendations! Published in 2017 at "Immunologic Research"
DOI: 10.1007/s12026-017-8930-2
Abstract: Microglial cells play a crucial role in inflammatory responses in neural tissue. Vitamin D (VitD3) deficiency is associated with the pathogenesis of inflammation. Staphylococcal enterotoxin B (SEB) is a superantigen and can initiate inflammation. This… read more here.
Keywords: staphylococcal enterotoxin; seb; expression tumor; expression ... See more keywords
Prognostic significance of PD-L1 expression on tumor cells and tumor-infiltrating mononuclear cells in upper tract urothelial carcinoma
Sign Up to like & getrecommendations! Published in 2017 at "Medical Oncology"
DOI: 10.1007/s12032-017-0941-2
Abstract: Immunotherapy targeting the programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) pathway has shown promising results in several malignancies. However, the prognostic significance of PD-L1 expression remains unknown in patients with upper tract urothelial carcinoma (UTUC). This… read more here.
Keywords: significance expression; expression tumor; tumor cells; expression ... See more keywords
PD‐L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2016.09.002
Abstract: Introduction: Therapeutic antibodies to immune checkpoints show promising results. Programmed death‐ligand 1 (PD‐L1), an immune checkpoint ligand, blocks the cancer immunity cycle by binding the PD‐L1 receptor (programmed death 1). We investigated PD‐L1 protein expression… read more here.
Keywords: protein expression; expression tumor; tumor cells; mrna ... See more keywords
Correlation of PD‐L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early‐Stage Squamous Cell Lung Carcinoma
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2018.09.006
Abstract: Objectives: Anti–programmed cell death 1 (PD‐1)/programmed death ligand 1 (PD‐L1) immunotherapy has demonstrated success in the treatment of advanced NSCLC. Recently, PD‐1/PD‐L1 blockade also has demonstrated interesting results in small trials of neoadjuvant treatment in… read more here.
Keywords: expression tumor; expression; early stage; gene ... See more keywords
Understanding the Chemical Characteristics of Payloads and the Expression of Tumor-Associated Antigens of ADCs in Clinical Development
Sign Up to like & getrecommendations! Published in 2025 at "ACS Omega"
DOI: 10.1021/acsomega.5c09181
Abstract: Antibody–drug conjugates (ADCs) have become one of the most promising therapeutic strategies for the treatment of cancer. This family of agents is composed of an antibody, a cytotoxic drug, and a linker that conjugates the… read more here.
Keywords: expression tumor; clinical development; chemical characteristics; expression ... See more keywords
BIOM-14. CD44 EXPRESSION IN THE TUMOR PERIPHERY PREDICTS THE RESPONSIVENESS TO BEVACIZUMAB IN THE TREATMENT OF RECURRENT GLIOBLASTOMA
Sign Up to like & getrecommendations! Published in 2025 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noaf201.0102
Abstract: Antiangiogenic therapy with bevacizumab (Bev), a monoclonal antibody targeting vascular endothelial growth factor (VEGF), is a common treatment for recurrent glioblastoma (GBM), but its survival benefit is limited due to resistance to Bev. To optimize… read more here.
Keywords: expression tumor; periphery; bev; cd44 ... See more keywords
Modifying factors of PD‐L1 expression on tumor cells in advanced non‐small‐cell lung cancer
Sign Up to like & getrecommendations! Published in 2022 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.14695
Abstract: Programmed death ligand‐1 (PD‐L1) expression predicts immunotherapy utility in nononcogenic addictive lung adenocarcinoma (ADC). However, its reproducibility and reliability may be compromised outside clinical trials. This study aimed to evaluate factors associated with PD‐L1 expression… read more here.
Keywords: factors expression; modifying factors; lung; expression tumor ... See more keywords
G6PD functions as a metabolic checkpoint to regulate granzyme B expression in tumor-specific cytotoxic T lymphocytes
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-003543
Abstract: Background Granzyme B is a key effector of cytotoxic T lymphocytes (CTLs), and its expression level positively correlates with the response of patients with mesothelioma to immune checkpoint inhibitor immunotherapy. Whether metabolic pathways regulate Gzmb… read more here.
Keywords: tumor specific; g6pd; expression; checkpoint ... See more keywords